Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rigosertib,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Onconova Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration will leverage Pangea Biomed’s proprietary algorithmic platform, ENLIGHT, for identifying biomarkers of response to Onconova’s proprietary investigational ON-01910 (rigosertib) with the ability to potently inhibit PLK1 to treat a ran...
Brand Name : ON-01910
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 23, 2023
Lead Product(s) : Rigosertib,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Onconova Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?